A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia
- 30 May 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 61 (9), 2191-2199
- https://doi.org/10.1080/10428194.2020.1762878
Abstract
High-dose cytarabine (HiDAC) consolidation for acute myeloid leukemia (AML) induces transient profound myelosuppression and potential morbidity/mortality. PrE0901 was a phase I multi-center trial evaluating the safety/toxicity of eltrombopag in AML patients receiving HiDAC consolidation. We used a standard 3 + 3 design employing a unique dose-escalation/de-escalation strategy. One hundred four patients were screened, 54 declined participation, 35 were deemed medically ineligible, and 14 were treated on study. Three patients were treated in cohorts 1–4 and two were treated in cohort 5. Eltrombopag + HiDAC was well-tolerated and no dose-limiting toxicities were observed. Median time to platelet recovery of all patients treated was 22.5 (range 16–43) days. Observationally, eltrombopag 150 mg once daily starting on day 3 of consolidation demonstrated the fastest and most consistent platelet recovery (median 19 days). Further investigation is needed to define the optimal role, dose, and schedule of eltrombopag in the treatment of chemotherapy associated myelosuppression.This publication has 25 references indexed in Scilit:
- Eltrombopag for post-transplant cytopenias due to poor graft functionBone Marrow Transplantation, 2019
- Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2017
- Low Doses of Eltrombopag Are Safe and Effective in the Prophylaxis of the Chemotherapy-Induced Thrombocytopenia (CIT)Blood, 2016
- Detection of septic transfusion reactions to platelet transfusions by active and passive surveillanceBlood, 2016
- Eltrombopag with gemcitabine‐based chemotherapy in patients with advanced solid tumors: a randomized phase I studyCancer Medicine, 2014
- Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamideBMC Cancer, 2013
- A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumorsCurrent Medical Research and Opinion, 2010
- Dose of Prophylactic Platelet Transfusions and Prevention of HemorrhageThe New England Journal of Medicine, 2010
- Anemia Management in Oncology and HematologyThe Oncologist, 2009
- Benefits of GM-CSF Versus Placebo or G-CSF in Reducing Chemotherapy-Induced Complications: A Systematic Review of the LiteratureSupportive Cancer Therapy, 2004